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Abstract 
 
Background: Meta-analyses of trials comparing thrombolysis and primary angioplasty 
following an acute myocardial infarction (AMI) have shown benefits for angioplasty.  
Choice of therapy needs to consider the relationship between this benefit and any time 
delay in initiating angioplasty.   
Objective: To extend earlier meta-analyses of these alternative forms of reperfusion by 
considering both 1- and 6-month outcome data.  To use Bayesian statistical methods to 
quantify more fully the uncertainty associated with the estimated relationships.  
Methods: A systematic review and meta-analysis published in 2003 was updated with 
recently published trials.  Data on key clinical outcomes and the difference between time-
to-balloon and time-to-needle were independently extracted by two researchers.  Bayesian 
statistical methods were used to synthesise evidence despite differences between trials in 
follow-up times and reported outcomes.  Outcomes are presented as absolute probabilities 
of specific events and odds ratios (with 95% credible intervals (CrI)) as a function of the 
additional time-delay associated with angioplasty.   
Results: A total of 22 studies were included in the meta-analysis, with 3,760 and 3,758 
patients randomised to primary angioplasty and thrombolysis, respectively.  The mean 
angioplasty-related time delay (over and above time to thrombolysis) was 54.3 minutes 
(S.E. 2.2).  For this average delay, the mean event probabilities are lower for primary 
angioplasty for all outcomes. Mortality within 1 month is 4.5% following angioplasty and 
6.4% after thrombolysis (odds ratio of 0.68 (95% CrI 0.46, 1.01)).  For non-fatal re-
infarction, the odds ratio is 0.32 (95% CrI 0.20, 0.51); and for non-fatal stroke it is 0.24 
(95% CrI 0.11, 0.50).  For all outcomes, the benefit of angioplasty decreases with longer 
delay from initiation.     
Conclusions: The benefit of primary angioplasty, over thrombolysis, depends on the 
former’s additional time delay.   For delays between 30 and 90 minutes, angioplasty is 
superior, on average, for 1-month fatal and non-fatal outcomes. Thrombolysis may be the 
preferred option in terms of 6-month mortality only for delays at around 90 minutes and 
beyond but there is considerable uncertainty for longer time delays. 
 
 
Keywords: Acute myocardial infarction, primary coronary angioplasty, thrombolytics, meta-
regression. 
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INTRODUCTION 
In the UK, at least 87,000 individuals under the age of 75 years suffer an acute myocardial 
infarction (AMI) each year.1 The relationship between normal coronary artery blood flow 
and mortality after MI is well documented,2 so early restoration of normal myocardial 
blood flow is a prime therapeutic goal for the management of MI. Pharmacological 
treatment with thrombolytic therapy and primary angioplasty are two different modes of 
reperfusion therapy for ST elevation AMI (STEMI).  
 
Meta-analyses of the various randomised trials comparing thrombolysis and primary 
angioplasty have shown substantial benefits from angioplasty in terms of mortality, non-
fatal re-infarction and stroke;2-5 and they have also shown that angioplasty has lower 
recurrence rates and less residual stenosis.6,7 Despite the apparent clinical superiority of 
primary angioplasty, thrombolytic treatment is the default treatment option in many 
countries because of practical limitations on the use of percutaneous interventions 
including a shortage of cardiac catheter facilities and appropriately skilled staff.  The choice 
of appropriate management also needs to consider the possible time delay in initiating 
reperfusion with primary angioplasty compared to thrombolysis. The effect of this 
angioplasty-related time delay in reducing the mortality benefit of angioplasty relative to 
thrombolysis has been demonstrated using meta-regression methods.8,9
 
This work has been influential in clinical guidelines for the management of AMI.10,11 For 
example, European guidelines suggest that primary angioplasty is the “preferred treatment 
if performed by an experienced team less than 90 minutes after first medical contact”.11  
However, there are some limitations in the analyses informing these guidelines.  A key 
meta-analysis only had abstracts available for some trials,2 and inaccuracy in data extraction 
has been observed.12  The quantification of the relationship between the benefit of 
angioplasty and time delay until its initiation did not quantify the uncertainty around this 
relationship, and the analysis was restricted to a sub-set of major clinical events.8   
 
This paper seeks to build on these previous analyses by extending their scope and statistical 
rigor.  It assesses how the treatment effect of angioplasty on fatal and non-fatal outcomes 
(re-infarctions and strokes) relates to the additional delay involved in initiating angioplasty.  
It also considers both the 1-month and the 6-month outcome data reported in randomised 
clinical trials.  Furthermore, in using Bayesian statistical methods, the paper is able to 
quantify more fully the uncertainty associated with the estimated relationships.   
 
METHODS 
Search strategy and data extraction 
To identify trials comparing intravenous thrombolysis and primary angioplasty in patients 
with STEMI, the analysis used an earlier review2 as a starting point. To update this review, 
the following databases were searched: Cochrane Controlled Trials Register, UK National 
Research Register, Medline, Embase, Database of Abstracts of Reviews of Effects, UK 
National Health Service Economic Evaluation Databases, and Health Technology 
Assessment Database.  The searches were restricted to English-language studies published 
between 2002 and 2004. The inclusion criteria were consistent with those used 
previously.2,5  Full details of the search strategy are available in a technical report {note to 
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the editor: a technical report is submitted with this paper with a view to web-based 
publication}. 
 
Two researchers (YB, CA) independently extracted the clinical data. Outcomes of interest 
were mortality, non-fatal re-infarctions, fatal and non-fatal strokes, and hemorrhagic 
strokes, as well as any data regarding time delay to treatment initiation.  Discrepancies were 
resolved by consensus, and a third researcher (SP) was consulted when necessary.  Data 
were also extracted on the difference between time-to-balloon in angioplasty and time-to-
needle in thrombolytic therapy.  This definition emphasises the differences in times to 
initiation of treatment between the two reperfusion strategies, thus avoiding the problem of 
different timing definitions across studies.  Mean times to treatment, together with their 
standard deviations, were preferred in the analysis, but medians and quartiles were used 
when these were not available.  Where the earlier review2 had used preliminary data from 
conference abstracts, these were updated with final trial reports; the earlier data extraction 
was also checked and any inaccuracies were corrected.    
 
Statistical methods   
The comparison in the meta-analysis was between primary angioplasty and thrombolysis 
(regardless of type of drug).  Because only a limited number of trials reported 6-month data 
on fatal or hemorrhagic strokes, these endpoints were excluded from the meta-analysis.  
Thus three outcomes (death, non-fatal strokes, and non-fatal re-infarctions), for which 
sufficient data were available, were analysed using an intention-to-treat principle. 
 
The analysis was undertaken using Bayesian statistical methods.13-15 These methods were 
used because they are more suitable for synthesising evidence when there are differences 
between trials in, for example, follow-up times and reported outcomes.  An important 
feature of Bayesian methods is that they use external evidence (so called ‘prior 
distributions’) which represent beliefs about the evidence and its uncertainty external to the 
data extracted from the trials.  This analysis has used ‘non-informative’ prior distributions 
so that the data are dominant in the results presented.  A sensitivity analysis was 
undertaken to verify that changing the specification of the prior distribution did not alter 
the results substantially.  Bayesian methods also enable direct probability statements to be 
made about quantities of clinical interest, e.g. the probability that an intervention is 
superior to another. 13,14
 
Full details of the statistical methods are presented in the technical report.  Briefly, the 
meta-analysis models all outcomes of interest as probabilities on the log-odds scale, and 
results are reported in terms of the absolute probability of specific events and odds ratios 
(with 95% credible intervals (CrI)).  It is assumed that baseline event rates (i.e. clinical 
events in the thrombolysis arms) vary randomly between trials, where the degree of 
variation is estimated from the data (a ‘random effect’ assumption).  That is, although the 
patient populations in different trials are not identical, they are similar to each other.  So 
the results of the analysis are only valid for patient populations similar to a hypothetical 
‘average’ trial population.   
 
For each outcome measure, the relative treatment effect of primary angioplasty compared 
to thrombolytic treatment is modelled as a ‘random effect’; similar but not identical 
between trials.  This relative treatment effect is estimated as a function of the time delay 
related to the initiation of angioplasty.  This relationship is used to establish the extent to 
which any additional effectiveness of angioplasty is affected by the additional time it takes 
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to deliver the intervention compared to thrombolysis, whilst taking into account the 
uncertainty surrounding the average delay in each trial.  When interpreting the results of 
such a ‘meta-regression’, caution is needed in extrapolating the relationship beyond the data 
on time delay observed in the trials.  Also, it should be recognised that, at the extremes of 
the time delay data, uncertainty in the estimates relationship will be greater than around the 
mid-point.   
 
A feature of the evidence base is that some trials report outcomes at 1 month follow-up, 
some at 6 months follow-up and some at both.  In order that all these data can be used, 
outcomes at 1 month and 6 months are assumed to differ by a random effect.16 This 
reflects the fact that clinical events are more likely to occur within the first month following 
AMI and, by allowing a relationship between outcomes at the two time-points, more of the 
data can be used in the analysis. Thus, those studies which do not report at 6 months can 
‘borrow strength’ both from those that do and from their own results at 1 month. 
 
RESULTS 
Summary of the trial evidence 
A total of 24 studies met the inclusion criteria.  Two of the studies were subsequently 
excluded from the meta-analysis.  One of these was excluded because it did not report 
times to treatment and, as such, could not provide data on the delay to primary 
angioplasty.17 The SHOCK study18 was also excluded because the primary comparison was 
between emergency revascularization without differentiating results by type of intervention 
(angioplasty 64%, surgery 36%), and hence this treatment strategy is not directly 
comparable with primary angioplasty in the other trials.  
 
Table 1 lists the remaining 22 studies included.  In comparison with the earlier review,2 one 
additional trial19 was identified which had not been published at the time. In addition, full 
trial results were available for three studies that had previously been reported in abstract 
form only.20-22  
 
Table 1 lists the data extracted from the 22 trials.  In total, these trials included 3,760 and 
3,758 patients randomised to primary angioplasty and thrombolysis, respectively.  Eight of 
the 22 trials used streptokinase as the form of thrombolysis, and 14 used t-PA.  For 
angioplasty, 13/22 trials used coronary stents, and 8 studies used glycoprotein IIb/IIIa 
antagonists.  The mean value of angioplasty-related time delay (over and above time to 
thrombolysis) was 54.3 minutes (S.E. 2.2).  All trials reported outcomes at between 30 days 
and 6 weeks (both are referred to as ‘1 month’ in the meta-analysis results) after the initial 
MI; 10 out of the 22 trials also reported outcomes at 6 months follow-up.  
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Table 1. Overview of trials and key endpoints and time to treatment for primary angioplasty (A) and thrombolysis (T).   
 
1 month (4-6 weeks) 6 months Time  
(minutes) 
N Death NF Reinfarction NF Stroke N Death    NF Reinfarction NF Stroke Mean Mean
 
 
 
Study  (A)         (T) N
(A)/(T) 
O.R. 
(95% CrI) 
N 
(A)/(T) 
O.R. 
(95% CrI)
N 
(A)/(T) 
O.R. 
(95% CrI) 
(A) (T) N
(A)/(T) 
O.R. 
(95% CrI) 
N  
(A)/(T) 
O.R. 
(95% CrI) 
N  
(A)/(T) 
O.R. 
(95% CrI) 
(A) (A)
Zijlstra et al 
199323§ 70 72 0 / 4 
0.1 
(0 – 7.7) 0 /9 
0.1 
(0.0 – 4.8) 0 / 2 
0.2 
(0.0 – 12.4) -          - - - - - - - 61 30
Ribeiro et al 
199324§ 50 50 3 / 1 
3.1 
(0.2 – 16) 4 / 5 
0.7 
(0.2 – 3.5) -           - - - - - - - - - 238 179
Zwolle  
1994§19 152 149 3 / 11 
0.3 
(0.2 – 2) 2 / 15 
0.1 
(0.0 – 1.7) 1 / 2 
0.4 
(0.0 – 8.1) -         - - - - - - - 195 176
Berrocal et al 
200320§ 54 58 5 / 6 
0.9 
(0.3 – 3.3) 1 / 2 
0.5 
(0.0 – 8.6) -            - - - - - - - - - 82 15
Zijlstra et al 
199725§ 45 50 1 / 0 
2.3 
(0 – 43) 0 / 8 
0.0 
(0.0 – 5.2) 1 / 2 
0.5 
(0.0 – 8.7) 45 50 1 / 0 
2.2 
(0.0 – 43.4) 0 / 8 
0.0 
(0.0 – 5.2) 1 / 2 
0.5 
(0.0 – 8.7) 68  29
Widimsky et al 
200026§ 101 99 7 / 14 
0.5 
(0.3 – 1.8) 1 / 10 
0.0 
(0.0 – 2.7) 0 / 0 
1 
(0.0 – 50.4) -          - - - - - - - 96 90
de Boer et al 
200227§ 46 41 3 / 8 
0.3 
(0.1 – 2.4) 1 / 6 
0.1 
(0.0 – 3.5) 1 / 2 
0.4 
(0.0 – 7.9) -          - - - - - - - 59 31
Widimsky et al 
200321§† 429 421 29 / 42 
0.7 
(0.5 – 1.4) 6 / 13 
0.4 
(0.2 – 1.8) 1 / 9 
0.1 
(0.0 – 3.0) -          - - - - - - - 97 12
DeWood et al 
199028 46 44 3 / 2 
1.5 
(0.2 – 7.4) -             - - - - - - - - - - - 126 84
Grines et al 
199329 195 200 5 / 13 
0.4 
(0.2 – 1.9) 5 / 13 
0.3 
(0.2 – 1.8) 0 / 3 
0.1 
(0.0 – 9.2) 188 190 7 / 15 
0.4 
(0.2 – 1.7) -      - - - 60 32
Gibbons et al 
199330 47 56 2 / 2 
1.2 
(0.1 – 8) - - - - 47 56 3 / 2 
1.8 
(0.2 – 8.1) 0 / 2 
0.2 
(0.0 – 13.2) -   - 277 232
Ribichini et al 
199831 55 55 1 / 3 
0.3 
(0.1 – 6.1) 1 / 2 
0.4 
(0.0 – 8.3) 0 / 0 
1 
(0.0 – 51.31) 55 55 1 / 4 
0.2 
(0.0 – 4.9) 2 / 2 
1 
(0.1 – 7.3) -   - 53.2 36.5
Garcia  et al 
199932 109 111 3 / 12 
0.2 
(0.1 – 1.9) 4 / 6 
0.6 
(0.2 – 3.0) 0 / 2 
0.2 
(0.0 – 12.3) 99 91 5 / 13 
0.3 
(0.2 – 1.7) 6 / 8 
0.6 
(0.2 – 2.5) -   - 197 150
GUSTO IIb 
199733 565 573 32 / 40 
0.8 
(0.6 – 1.5) 25 / 37 
0.6 
(0.4 – 1.4) 1 / 5 
0.2 
(0.0 – 4.2) 565 573        - - - - - - 228 180
Le May et al 
200134 62 61 3 / 2 
1.5 
(0.2 – 7.4) 3 / 5 
0.5 
(0.1 – 3.4) 1 / 1 
1 
(0.0 – 16.2) 62 61 3 / 2 
1.5 
(0.1 – 7.3) 4 / 10 
0.3 
(0.1 – 2.1) 1 / 3 
0.3 
(0.0 – 6.0) 77  15
Bonnefoy et al 
200235 421 419 20 / 16 
1.3 
(0.6 – 2.2) 7 / 15 
0.4 
(0.2 – 1.7) 0 / 4 
0.1 
(0.0 – 7.6) -         - - - - - - - 190 130
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Schomig et al 
200036 71 69 3 / 5 
0.6 
(0.2 – 3.4) 2 / 4 
0.4 
(0.1 – 4.0) - - 71 69 3 / 9 
0.2 
(0.1 – 2.2) -      - - - 65 30
Vermeer  et al 
199937† 75 75 5 / 5 
1 
(0.3 – 036) 1 / 7 
0.1 
(0.0 – 3.4) 2 / 1 
2 
(0.1 – 15.3) -          - - - - - - - 85 10
Kastrati et al 
200238 81 81 2 / 5 
0.4 
(0.1 – 3.5) 0 / 4 
0.1 
(0.0 – 7.6) 1 / 1 
1 
(0.0 – 16.2) 70 71 5 / 7 
0.7 
(0.2 – 2.8) -      - - - 75 35
Aversano et al 
200239 225 226 12 / 16 
0.7 
(0.4 – 1.9) 11 / 20 
0.5 
(0.3 – 1.6) 3 / 8 
0.3 
(0.1 – 2.4) 225 226 14 / 16 
0.8 
(0.4 – 1.9) 12 / 24 
0.4 
(0.3 – 1.4) 5 / 9 
0.5 
(0.2 – 2.3) 101.5  46
Grines et al 
200240 71 66 6 / 8 
0.7 
(0.3 – 2.6) 1 / 0 
1.8 
(0 – 39.7) 0 / 3 
0.1 
(0.0 – 8.9) -         - - - - - - - 174 63
Andersen et al 
2003: Referral22* 567 562 37 / 48 
0.7 
(0.6 – 1.4) 11 / 35 
0.2 
(0.2 – 1.1) 9 / 11 
0.8 
(0.3 – 2.2) -          - - - - - - - 90 20
Andersen et al 
2003: Invasive22* 223 220 15 / 13 
1.1 
(0.5 – 2.3) 2 / 14 
0.1 
(0.0 – 1.8) 0 / 5 
0.0 
(0.0 – 6.6) -          - - - - - - - 63 20
 
Reinf. = reinfarction; SD = standard deviation; CrI = credibility interval  
*  This trial consisted of two sub-trials, labelled ‘Referral’ and ‘Invasive’, and these are analysed as if they are two separate studies. † Includes a third group of patients who received thrombolytic therapy 
followed by transfer to angioplasty; these third comparators were excluded from the present analysis. § Trial used streptokinase as part the thrombolytic arm, all other trials used t-PA. 
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Meta-analysis 
Table 2 shows the estimated probability of each outcome occurring within 1 month or 6 months 
after initial treatment with primary angioplasty or thrombolytics.  These results are based on the 
average angioplasty-related time delay of 54.3 minutes reported in the trials, estimated as a 
weighted average, the weights being the total number of patients in each trial. For all outcomes, 
the mean probability of an event occurring is lower for patients randomised to primary 
angioplasty.  In particular, mortality within 1 month is estimated to be 4.5% following angioplasty 
and 6.4% after thrombolysis, with an odds ratio of 0.68 (95% CrI 0.46, 1.01).   For non-fatal re-
infarction, the odds ratio is 0.32 (95% CrI 0.20, 0.51); and for non-fatal stroke it is 0.24 (95% CrI 
0.11, 0.50).  Table 2 also shows estimated results for the 6-month endpoints which are very 
similar to those at 1 month, indicating that the majority of events happen in the first month after 
randomisation. 
 
As the additional time delay to initiation of primary angioplasty is modelled explicitly, it is 
possible to predict how particular angioplasty-related time delays influence the clinical superiority 
of angioplasty.  For angioplasty delays of 30, 60 or 90 minutes, the absolute probability 
differences and the odds-ratios of angioplasty versus thrombolytic therapy are shown in Table 3.  
If angioplasty could be initiated within 30 minutes of possible thrombolysis, the absolute 
probabilities of mortality, non-fatal re-infarction and non-fatal stroke at 6 months would be, 
respectively, 3.7%, 4.6% and 1.7% lower than those with thrombolysis.  For any of these 
outcomes, the benefit of angioplasty decreases with longer delay until its initiation.  
 
This effect is shown in more detail in Figure 1.  In terms of mortality, angioplasty is superior to 
thrombolysis, on average, at time delays up to 90 minutes.  Moreover, in terms of the 1-month 
outcome of mortality, the probability that it is superior is 97%, for an additional delay of up to 
around 60 minutes.  For the 6-month outcome of mortality, there is over 95% probability that 
angioplasty is superior for delays of up to around 45 minutes and 87% for delays up to around 60 
minutes. However, this probability goes below 50% for delays at 90 minutes and beyond, where 
thrombolysis could therefore be the preferred option at least for the 6-month mortality outcome.  
For non-fatal re-infarction and non-fatal stroke, primary angioplasty is superior, on average, even 
if it requires an additional time of up to 2 hours to achieve reperfusion with that method.  For 
both non-fatal outcomes at one month, there was over 95% probability that angioplasty is 
superior at additional delays of up to 90 minutes.  For the corresponding 6-month outcomes, 
there was over 95% probability that angioplasty was superior at delays up to 80 minutes.   
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Table 2.  Estimated absolute probabilities of the occurrence of various endpoints 1 month 
or 6 months after angioplasty or thrombolytic therapy (mean and 95% CrI), together with 
the odds ratios (95% CrI) comparing primary angioplasty and thrombolysis and 
probabilities that angioplasty is superior.  The results are for the average observed 
‘angioplasty-related time delay’ (i.e. 54.3 minutes).   
 
1-month endpoints Probability 
(angioplasty) 
Probability 
(thrombolytics) Odds ratio 
Probability 
angioplasty 
superior  
Death 4.5% 
(3.0%, 6.5%) 
6.5%  
(4.5%, 9.0%) 
0.68 
(0.46, 1.01) 
0.97 
Non-fatal reinfarction 2.0% 
(1.2%, 3.1%) 
6.1% 
(4.1%, 8.5%) 
0.33 
(0.20, 0.51) 
1.00 
Non-fatal stroke 0.5% 
(0.2%, 0.9%) 
1.9% 
(1.0%, 3.2%) 
0.26 
(0.11, 0.50) 
1.00 
     
6-month endpoints Probability 
(angioplasty) 
Probability 
(thrombolytics) 
Odds ratio Probability 
angioplasty 
superior 
Death 5.5% 
(3.4%, 8.8%) 
7.7% 
(5.0%, 11.8%) 
0.70 
(0.42, 1.18) 
0.93 
Non-fatal reinfarction 2.6% 
(1.4%, 4.8%) 
6.9% 
(4.4%, 10.7%) 
0.33 
(0.20, 0.67) 
0.99 
Non-fatal strokes 0.8% 
(0.2%, 1.0%) 
2.8% 
(1.1%, 6.9%) 
0.26 
(0.08, 0.72) 
0.99 
 
 
 
 9
Table 3. Absolute probability differences (thrombolysis minus angioplasty), odds ratios for the 6-month treatment effects of angioplasty 
compared to thrombolytic therapy (mean and 95% CrI) and probability that angioplasty is superior at assumed ‘angioplasty-related time 
delays’ of 30, 60 and 90 minutes.   
 
 Primary angioplasty-related time delay 
 30 minutes 60 minutes 90 minutes 
Endpoint  Probability
difference 
(95% CrI) 
Odds ratio Probability 
angioplasty is 
a superior 
treatment  
Probability 
difference 
(95% CrI) 
Odds ratio Probability 
angioplasty 
is a superior 
treatment  
Probability 
difference  
(95% CrI) 
Odds ratio Probability 
angioplasty is a 
superior 
treatment  
Death –3.5% (–7.2%, –0.5%) 
0.54 
(0.29, 0.92) 
0.98    –1.8%
(–5.6%, +1.7%) 
0.77 
(0.44, 1.29) 
0.87 +0.7%
(–4.6%, +8.1%) 
1.15 
(0.49, 2.36) 
0.44 
Non-fatal 
re-infarction 
–4.8% 
(–8.2%, –2.2%) 
0.30 
(0.14, 0.59) 
0.99    –4.2%
(–7.5%, –1.6%) 
0.39 
(0.21, 0.72) 
0.97 –3.1%
(–7.1%, +1.6%) 
0.55 
(0.2,9 1.27) 
0.93 
Non-fatal 
stroke 
–2.1% 
(–5.8%, –0.5%) 
0.47 
(0.05, 0.69) 
0.99    –2.0%
(–5.6%, –0.4%) 
0.56 
(0.09, 0.75) 
0.98 –1.6%
(–5.3%, +0.8%) 
0.79 
(0.08, 1.43) 
0.93 
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Figure 1. Treatment effect of primary angioplasty relative to thrombolytic therapy, in terms of the absolute 
probability differences for each key outcome (death, non-fatal re-infarctions, non-fatal strokes) and point of 
follow-up (1-month, 6-month).  The graphs show means and 95% CrIs plotted against the additional time 
delay to initiating primary angioplasty. Values above the x-axis indicate that angioplasty results in fewer 
clinical events.  Each point represents a trial and their size is proportional to the trial sample size.  
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DISCUSSION 
The contribution of this review is twofold.  Firstly, it updates the most comprehensive 
recent meta-analysis of randomised trials comparing primary angioplasty and 
thrombolysis in patients with STEMI.2 Secondly, it extends the evidence synthesis by 
evaluating the relationship between the treatment effects of angioplasty and time delay, 
expressed as the difference in times to initiation of treatment between the two 
reperfusion strategies. Furthermore, to our knowledge, this is the first study that 
explicitly models the measurement uncertainty associated with angioplasty-related time 
delay. 
 
Although Keeley et al2 do not directly address the issue of time delay, the main results in 
that study can be compared with those presented here for the average time delay of 54.3 
minutes.  For mortality at 1 month, Keeley et al found an odds ratio of 0.70 (95% 
confidence interval 0.58, 0.85), which is similar to that reported here, although our 
estimate does not reach statistical significance.  This lack of statistical significance is likely 
to be due to differences in the data extraction,12 the inclusion of additional evidence, and 
also because the measurement uncertainty in the time delay covariate is explicitly 
considered here.  For the outcome of non-fatal re-infarction, the results here are similar 
to those of Keeley et al, in terms of both the magnitude and uncertainty of the odds ratio. 
The analysis of the stroke outcome is not comparable to that in Keeley et al which 
included all strokes compared to the non-fatal strokes considered here. Although a 
separate analysis of the longer-term follow-up data was undertaken by Keeley et al, these 
results were not presented in sufficient detail to allow a reliable comparison between the 
two sets of analyses at 6 months. Another reason why there will be slight differences 
between the two meta-analyses is that in ours the uncertainty in the between-study 
variability of the effect is appropriately taken in to account thus producing slightly wider 
CrIs than those obtained using Classical meta-analysis methods.14,15  
 
Based on research undertaken during a similar period to our own, Boersma et al.41 have 
also recently demonstrated, using individual patient data from 22 trials, that angioplasty is 
associated with significantly lower 30-day mortality, re-infarction and stroke relative to 
thrombolysis, regardless of delay in presentation. The main results in that study for the 
overall angioplasty-related delay of 55 minutes can be compared with those presented 
here for the average time delay of 54.3 at 1-month (Table 2) although there were minor 
differences in the trials included in the two studies.  The absolute differences in the risks 
of non-fatal MI and stroke between angioplasty and thrombolysis at one month were 
very similar (4.3% vs 4.1% for non-fatal MI and 1.7% vs 1.4% for non-fatal stroke in 
Boersma et al and the current study, respectively). The estimated absolute reduction in 
mortality risk with angioplasty at one month was higher in the Boersma et al study: 2.6% 
versus 2%.  As seen in previous studies,8,42 the benefit of angioplasty in terms of mortality 
decreases the longer the time delay to initiation of angioplasty.  However, none of these 
studies (including Boersma et al.41) quantify the uncertainty in this relationship fully. The 
comprehensive handling of uncertainty in the current analysis allows the precision 
associated with the relationship to be presented (Figure 1).  The Bayesian approach also 
facilitates the presentation of results in terms of the probability of one intervention of 
being the superior treatment.   
 
This is the first study to link explicitly short-term (1 month) with longer-term (6 months) 
outcomes using as much of the available clinical evidence as possible.  Although none of 
the trial data indicate systematic differences between the relative treatment effect of 
primary angioplasty at 1 month and at 6 months, fewer data are generally available at 6 
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months resulting in greater uncertainty.  It is, therefore, not surprising that the point 
estimates of the relative treatment effect of angioplasty are similar at the two time-points, 
but with greater uncertainty at 6-month endpoints. Thus, a probability of superiority of 
angioplasty in terms of the 6-month mortality endpoint of greater than 0.95 can be 
identified for delays of up to around 45 minutes only, whilst for delays at around 90 
minutes thrombolysis appears to be superior. However, angioplasty appears to be 
superior for 6-month non-fatal outcomes, on average, for delays up to around 90 
minutes. It should be noted, however, that the uncertainty in these relationships shown 
here is less than it would have been had only 6 month follow-up data been used in the 
analysis due to the paucity of the data. 
 
The analysis suggests, therefore, that angioplasty performs better than thrombolytic 
therapy but this superiority is related to angioplasty-related time delay.  It should be 
emphasised, however, that no trials have been identified which show a statistically 
significant advantage for thrombolysis at very long angioplasty-related time delays.  
Moreover, the PRAGUE-2 trial indicates that angioplasty performs better than 
thrombolysis even when it involves a patient transfer of up to 3 hours.21 Without more 
evidence at long angioplasty-related time delays, the linear regression model estimated 
here will inevitably indicate that the relative treatment effect of primary angioplasty 
becomes negative at an unspecified delay.  This is not because of data showing this 
effect, but simply because a consistent relationship has been observed for a range of 
relatively short time delays. In reality, for delays approaching 2 hours, this study can 
neither confirm nor refute whether angioplasty is better than thrombolytic treatment. 
 
This study has some limitations.  Firstly, the lack of individual patient data precludes the 
analysis of how the relative effect of angioplasty varies between patient sub-groups, and 
whilst this analysis has taken account of the uncertainty in the average time delay, thus 
reducing the possibility of ecological fallacy,43 the presence of an ecological bias cannot 
be entirely eliminated. However, this is less of an issue when it is recognized that the aim 
of this study is to provide evidence to support population-based decisions using cost-
effectiveness analysis as reported in the companion paper {ref to CE paper}.  However, 
an analysis of individual patient data would also enable a more appropriate estimate of 
the impact or otherwise of time delay on outcome to be obtained.44,45 Secondly, time-to-
needle is a predictor of the success of thrombolytic treatment, but this effect could not 
be included in the analysis explicitly due to inconsistent reporting of the data in the trials.  
Hence the results are based on the average time-to-needle in the studies considered, 
which, at 75 minutes, was shown to be similar to the median call to needle time (67 
minutes) in the UK (personal communication, Dr John Birkhead, UK Myocardial 
Infarction National Audit Project).  Further research would be desirable to identify all 
external evidence on the effect of time-to-needle on outcomes and incorporate this into 
our analysis via appropriate prior distributions taking account of relevance and quality.15    
Thirdly, given this review was an update of those published earlier, neither the effect of 
publication bias, study quality or the influence of individual studies were formally 
assessed on the overall meta-analysis results. Fourthly, further exploration of whether the 
potential relationship between time-delay and effect (log odds ratio) is linear may be of 
merit.  
 
The final limitation concerns the use of older streptokinase trials in the meta-analysis.  
Keeley et al were criticised46 for including these trials in their meta-analysis because, by 
effectively averaging across the thrombolytic trials, the additional benefit of angioplasty 
may have been over-estimated.  However, streptokinase is the most common form of 
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thrombolytic therapy used in many countries and is used in about a third of patients in 
the UK (personal communication, Dr John Birkhead, UK Myocardial Infarction 
National Audit Project).  In the present meta-analysis, the differences between 
thrombolytic drugs were ignored with a focus on primary angioplasty or thrombolysis as 
two treatment groups. If only t-PA trials were analysed, the relative benefit of primary 
angioplasty is attenuated: 1-month odds-ratios for mortality are found to be 0.71 (95% 
CrI 0.44, 1.16); for non-fatal re-infarction, 0.41 (95% CrI 0.23, 0.71); and for non-fatal 
strokes, 0.23 (95% CrI 0.08, 0.57). Full details of this sensitivity analysis are reported in 
the technical report. 
 
The policy implications of this analysis should be seen in the context of the relevant 
health care system. For example, US guidelines currently recommend that primary 
angioplasty should be used only within an angioplasty-related delay of less than 60 
minutes.10 The guidelines, however, seem to be based largely on the work of Nallamothu 
and Bates,8 and may be premature because angioplasty appears to convey health benefits 
even when the delay is longer than 60 minutes.  Even at delays longer than 1 hour, 
angioplasty is superior, on average, for all the 1-month outcomes included in this study, 
although there is considerable uncertainty associated with these estimates. 
 
What size of treatment effect would be necessary with primary angioplasty to be 
considered worthwhile given the major changes in service organization necessary for its 
implementation? This issue is considered directly in the cost-effectiveness analysis 
submitted as a companion paper, which addresses whether the health benefits of primary 
angioplasty are sufficient to justify its additional cost.  With respect to the absolute size 
of treatment effect with primary angioplasty, our analysis shows that the probability that 
primary angioplasty reaches at least a 1%, 2% and 3% improvement in survival at 1-
month relative to thrombolysis is 0.82, 0.47 and 0.15, respectively, at the average 
angioplasty-related time delay.  In short, the benefit of timely treatment is the key: If 
primary angioplasty can be delivered in a timely fashion, current evidence supports its 
use; if not, the choice of treatment probably depends on time from onset of symptoms 
to presentation21, 41 and the availability of pre-hospital thombolysis.35  
 
Decisions about appropriate methods of reperfusion should consider not only the 
effectiveness of each treatment option, but also their cost-effectiveness. With the 
quantification of both the expected treatment effects of angioplasty, with regard to 
several possible outcomes, and the uncertainties associated with these predictions, this 
meta-analysis using Bayesian methods lays the foundations for a robust cost-effectiveness 
analysis, in which other treatment strategies may be considered, and in which appropriate 
account is taken of statistical, clinical and methodological heterogeneity and all sources of 
uncertainty.47
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Technical Appendix  [Note to editor: this appendix could be web-based or 
published with the paper.] 
The results of the 22 trials identified were formally combined using meta-analytic 
approaches. A Bayesian evidence synthesis is implemented48 using specialist software 
(WinBUGS).49 A random-baseline, random-effects approach is adopted for each 
outcome measure50,51 that incorporates a linear regression of the treatment effect (log 
odds ratio) on the covariate “PCI-related time delay”.52  The model assumptions are 
described step by step below. 
 
Multiple outcomes 
In the trial search strategy we identified three clinical outcomes that are reported by a 
sufficient number of trials to inform an evidence synthesis: death, non-fatal strokes, and 
non-fatal re-infarctions. With such binomial outcomes, where an event either happens or 
does not happen, treatment effects can be modelled as absolute or relative risk 
differences or as log-odds.53  For numerical convenience, we model all treatment effects 
on the log-odds scale. To reflect slight differences in recruitment criteria and patient mix, 
for each outcome the baseline event rates are assumed to vary randomly around a 
common mean. 
 
Multiple time-points 
While all trials report outcomes at the 1-month endpoint, a number of trials also report 
clinical events at the 6-month endpoint. However, any event that has occurred by 1 
month will still have occurred by 6 months, so these endpoints are clearly related. 
Statistically, such a situation can be modelled by assuming that, for each treatment arm 
and outcome, the 1-month and the 6-month endpoints differ by a random effect, 
additive on the log-odds scale. We assume that these random effects are unrelated to the 
covariates that may explain some of the variation in the treatment effect of PCI 
compared to thrombolytic therapy.  
 
Treatment effect of PCI relative to thrombolysis  
For each trial and outcome, we model the treatment effect of PCI relative to 
thrombolysis as a random effect additive on the log-odds scale, respecting both the 
randomisation in the clinical trial and the heterogeneity of treatment effects measured by 
different trials. We assume that the same mean treatment effect of PCI, relative to 
thrombolysis, applies at both the 1-month and the 6-month time-point of each trial.  This 
assumption is supported in the trial reports, which show that most clinical events occur 
within a few days from the initial episode (e.g. Aversano et al39, Schomig et al54, Le May et 
al34, García et al32). We do not attempt to impute the 6-month data for those trials that did 
not report it and, therefore, the average treatment effect of PCI relative to thrombolytic 
therapy will be informed more strongly by the 1-month data that are reported more 
commonly.  The mean treatment effect of PCI, relative to thrombolysis, is modelled in 
terms of the covariate “PCI-related time delay” (i.e. the additional time to PCI over and 
above thrombolysis) by linear regression [e. g. Berkey et al 199852].  
Correlated outcomes 
We identify and model two sources of correlation between event rates.  Baseline log-odds 
for the three outcomes are correlated across trials (e. g. high baseline mortalities may 
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systematically coincide with elevated or reduced rates of non-fatal strokes). Also, within 
each outcome, we model correlation of the four endpoints (1-month and 6-month 
endpoints on two treatment arms), but we allow the exact nature of these correlations to 
vary dependent on outcome [e. g. van Houwelingen et al 200251].  We parameterise all the 
above correlations by multivariate normal distributions (on the log-odds scale).  
Covariate “PCI-related time delay” 
To model the measurement error in the covariate “PCI-related time delay”, we model 
independently the delays associated with each treatment (time to needle/balloon) as 
measured in each trial, and calculate the value of the covariate by subtraction. For each 
treatment arm, the trial reports give a summary statistic (i.e. mean with standard error, or 
median with confidence interval), which we have interpreted to obtain a prior mean and 
variance under the assumption of normality. For those trials that do not report the 
variability in times to treatment,26,28,37 we used the corresponding average values from the 
other trials. Because treatment effect in our model only depends on the “PCI-related 
time delay”, i.e. the difference between the delays in the two arms of each trial, it is 
irrelevant whether a trial measures the time from occurrence of symptoms to 
reperfusion, or from randomisation to beginning of treatment as long as both arms of 
the trial are consistent, and assuming that there is no within-trial correlation.  
 
Statistical Model 
Table A1 shows the equations used in the analysis for each component of the model. 
Throughout, let  index the trials and i  index the clinical endpoints. Also, let capital 
letters , 
j
N R  stand for the 6-month endpoint data, and small letters n , r  denote 1-
month endpoint data from the trials, for the two arms TPx ,=  (PCI or thrombolytics). 
Probabilities π  are estimated on the log-odds scale. Baseline probability log-odds are 
denoted by µ . Random effects are modelled as additive on the log-odds scale, and the 
mean underlying probabilities shall be denoted by λ . The log-odds differences between 
1-month and 6-month probabilities are denoted by ω . Time delays, as measured in each 
trial arm, shall be written as δ , their means as δ , and the observed variance as . The 
covariate “PCI-related time delay” is denoted by 
v
∂ , and the coefficients of the linear 
regression by α  (intercept) and β  (slope). 
 
Wishart prior distributions were used for the covariance matrices, in which the degrees of 
freedom were set to the rank of the covariance matrix, whilst for means and regression 
parameters Normal or half-Normal prior distributions were assumed in which hyper-
prior uniform distributions for the corresponding standard deviation were used.  
 
Parameter Estimation 
The parameters of the model were estimated using Markov Chain Monte Carlo (MCMC) 
methods as implemented in WinBUGS software 1.4.1.49 Convergence was assessed via 
sensitivity analyses with respect to initial values, length of ‘burn-in’ and length of sample, 
using both visual inspection of trace plots, and by running multiple chains assessed by 
the Gelman-Rubin convergence statistic.55 Final parameter estimates are based on a ‘burn 
in’ of 5,000 and a sample of 35,000 iterations. 
 
Sensitivity analyses with respect to prior distributions, especially for the covariance 
matrices were also undertaken. 
 
 16
Table A1.  The equations used in the analysis for each component of the model 
Model component Equations (for all i , , j x , where appropriate) 
Trial data ( )xjx jixji nBinr ,~ ,, π  and ( )xjx jix ji NBinR ,~ ,, Π  
Probabilities on logit 
scale x jix
ji
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ji
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x
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  where Xi is the between-time-point 
covariance matrix for the ith outcome and is assumed constant 
across trials. 
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effects 
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  where Y is the between-outcome 
covariance matrix for thrombolytic therapy and is assumed 
constant across trials. 
time delay covariate T
j
P
jj δδ −=∂  
Measurement error in 
time delay 
( )xjxjxj vN ,~ δδ  
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